The effect of citrulline and arginine supplementation on lactic acidemia in MELAS syndrome

Ayman W El-Hattab, Lisa T Emrick, Kaitlin C Williamson, William J Craigen, Fernando Scaglia, Ayman W El-Hattab, Lisa T Emrick, Kaitlin C Williamson, William J Craigen, Fernando Scaglia

Abstract

Mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) syndrome is a mitochondrial disorder in which nitric oxide (NO) deficiency may play a role in the pathogenesis of several complications including stroke-like episodes and lactic acidosis. Supplementing the NO precursors arginine and citrulline restores NO production in MELAS syndrome. In this study we evaluated the effect of arginine or citrulline on lactic acidemia in adults with MELAS syndrome. Plasma lactate decreased significantly after citrulline supplementation, whereas the effect of arginine supplementation did not reach statistical significance. These results support the potential therapeutic utility of arginine and citrulline in MELAS syndrome and suggest that citrulline supplementation may be more efficacious. However, therapeutic efficacy of these compounds should be further evaluated in clinical trials.

Keywords: Endothelial dysfunction; Lactic acidosis; Mitochondrial myopathy; Nitric oxide (NO); Stroke-like episodes; m.3243A>G heteroplasmy.

Figures

Fig. 1
Fig. 1
Scatter plot for the individual lactate values before and after arginine and before and after citrulline supplementations. Each point represents each research subject with plasma lactate level before supplementation plotted against the X axis and after supplementation plotted against the Y axis.

References

    1. Bai R.K., Wong L.J. Detection and quantification of heteroplasmic mutant mitochondrial DNA by real-time amplification refractory mutation system quantitative PCR analysis: a single-step approach. Clin. Chem. 2004;50:996–1001.
    1. Chinnery P.F., Turnbull D.M. Epidemiology and treatment of mitochondrial disorders. Am. J. Med. Genet. 2011;106:94–101.
    1. El-Hattab A.W., Hsu J.W., Emrick L.T. Restoration of impaired nitric oxide production in MELAS syndrome with citrulline and arginine supplementation. Mol. Genet. Metab. 2012;105:607–614.
    1. El-Hattab A.W., Emrick L.T., Craigen W.J., Scaglia F. Citrulline and arginine utility in treating nitric oxide deficiency in mitochondrial disorders. Mol. Genet. Metab. 2012;107:247–252.
    1. Förstermann U., Closs E.I., Pollock J.S. Nitric oxide synthase isozymes. Characterization, purification, molecular cloning, and functions. Hypertension. 1994;23:1121–1131.
    1. Goto Y., Horai S., Matsuoka T. Mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS): a correlative study of the clinical features and mitochondrial DNA mutation. Neurology. 1992;42:545–550.
    1. Green D.J., Maiorana A., O'Driscoll G., Taylor R. Effect of exercise training on endothelium-derived nitric oxide function in humans. J. Physiol. 2004;561:1–25.
    1. Hirano M., Pavlakis S.G. Mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes (MELAS): current concepts. J. Child Neurol. 1994;9:4–13.
    1. Kaufmann P., Engelstad K., Wei Y. Dichloroacetate causes toxic neuropathy in MELAS: a randomized, controlled clinical trial. Neurology. 2006;66:324–330.
    1. Koga Y., Akita Y., Nishioka J. L-arginine improves the symptoms of stroke-like episodes in MELAS. Neurology. 2005;64:710–712.
    1. Koga Y., Akita Y., Junko N. Endothelial dysfunction in MELAS improved by l-arginine supplementation. Neurology. 2006;66:1766–1769.
    1. Koga Y., Akita Y., Nishioka J. MELAS and L-arginine therapy. Mitochondrion. 2007;7:133–139.
    1. Mehrazin M., Shanske S., Kaufmann P. Longitudinal changes of mtDNA A3243G mutation load and level of functioning in MELAS. Am. J. Med. Genet. A. 2009;149:584–587.
    1. Mori M., Gotoh T. Regulation of nitric oxide production by arginine metabolic enzymes. Biochem. Biophys. Res. Commun. 2000;3:715–719.
    1. Naini A., Kaufmann P., Shanske S. Hypocitrullinemia in patients with MELAS: an insight into the “MELAS paradox”. J. Neurol. Sci. 2005;229:87–193.
    1. Ohama E., Ohara S., Ikuta F. Mitochondrial angiopathy in cerebral blood vessels of mitochondrial encephalomyopathy. Acta Neuropathol. 1987;74:226–233.
    1. Sacks D.B. In: Tietz Textbook of Clinical Chemistry. Second edition. Burtis C.A., Ashwood E.R., editors. W.B. Saunders Company; Philadelphia: 1994. Carbohydrates.
    1. Scaglia F., Northrop J.L. The mitochondrial myopathy encephalopathy, lactic acidosis with stroke-like episodes (MELAS) Syndrome: a review of treatment options. CNS Drugs. 2006;20:443–464.
    1. Shanske S., Pancrudo J., Kaufmann P. Varying loads of the mitochondrial DNA A3243G mutation in different tissues: implications for diagnosis. Am. J. Med. Genet. A. 2004;130:134–137.
    1. Sproule D.M., Kaufmann P. Mitochondrial encephalopathy, lactic acidosis, and strokelike episodes: basic concepts, clinical phenotype, and therapeutic management of MELAS syndrome. Ann. N. Y. Acad. Sci. 2008;1142:133–158.
    1. Tengan C.H., Kiyomoto B.H., Godinho R.O. The role of nitric oxide in muscle fibers with oxidative phosphorylation defects. Biochem. Biophys. Res. Commun. 2007;359:771–777.
    1. Toda N., Okamura T. The pharmacology of nitric oxide in the peripheral nervous system of blood vessels. Pharmacol. Rev. 2003;55:271–324.
    1. Vattemi G., Mechref Y., Marini M. Increased protein nitration in mitochondrial diseases: evidence for vessel wall involvement. Mol. Cell. Proteomics. 2011;10 (M110.002964)
    1. Villanueva C., Giulivi C. Subcellular and cellular locations of nitric oxide synthase isoforms as determinants of health and disease. Free Radic. Biol. Med. 2010;49:307–316.
    1. Wallace D.C. Diseases of the mitochondrial DNA. Annu. Rev. Biochem. 1992;61:1175–1212.
    1. Wallace D.C. Mitochondrial diseases in man and mouse. Science. 1999;283:1482–1488.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner